These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 31797633)

  • 1. Network-Based Matching of Patients and Targeted Therapies for Precision Oncology.
    Liu Q; Ha MJ; Bhattacharyya R; Garmire L; Baladandayuthapani V
    Pac Symp Biocomput; 2020; 25():623-634. PubMed ID: 31797633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved anticancer drug response prediction in cell lines using matrix factorization with similarity regularization.
    Wang L; Li X; Zhang L; Gao Q
    BMC Cancer; 2017 Aug; 17(1):513. PubMed ID: 28768489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting breast cancer drug response using a multiple-layer cell line drug response network model.
    Huang S; Hu P; Lakowski TM
    BMC Cancer; 2021 May; 21(1):648. PubMed ID: 34059012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. kESVR: An Ensemble Model for Drug Response Prediction in Precision Medicine Using Cancer Cell Lines Gene Expression.
    Majumdar A; Liu Y; Lu Y; Wu S; Cheng L
    Genes (Basel); 2021 May; 12(6):. PubMed ID: 34070793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal drug prediction from personal genomics profiles.
    Sheng J; Li F; Wong ST
    IEEE J Biomed Health Inform; 2015 Jul; 19(4):1264-70. PubMed ID: 25781964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Precision Oncology beyond Targeted Therapy: Combining Omics Data with Machine Learning Matches the Majority of Cancer Cells to Effective Therapeutics.
    Ding MQ; Chen L; Cooper GF; Young JD; Lu X
    Mol Cancer Res; 2018 Feb; 16(2):269-278. PubMed ID: 29133589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MD-Miner: a network-based approach for personalized drug repositioning.
    Wu H; Miller E; Wijegunawardana D; Regan K; Payne PRO; Li F
    BMC Syst Biol; 2017 Oct; 11(Suppl 5):86. PubMed ID: 28984195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multitask learning improves prediction of cancer drug sensitivity.
    Yuan H; Paskov I; Paskov H; González AJ; Leslie CS
    Sci Rep; 2016 Aug; 6():31619. PubMed ID: 27550087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SCNrank: spectral clustering for network-based ranking to reveal potential drug targets and its application in pancreatic ductal adenocarcinoma.
    Liu E; Zhang ZZ; Cheng X; Liu X; Cheng L
    BMC Med Genomics; 2020 Apr; 13(Suppl 5):50. PubMed ID: 32241274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identifying cell lines across pan-cancer to be used in preclinical research as a proxy for patient tumor samples.
    Bose B; Bozdag S
    Commun Biol; 2024 Sep; 7(1):1101. PubMed ID: 39244634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional Precision Medicine Identifies Novel Druggable Targets and Therapeutic Options in Head and Neck Cancer.
    Xu C; Nikolova O; Basom RS; Mitchell RM; Shaw R; Moser RD; Park H; Gurley KE; Kao MC; Green CL; Schaub FX; Diaz RL; Swan HA; Jang IS; Guinney J; Gadi VK; Margolin AA; Grandori C; Kemp CJ; Méndez E
    Clin Cancer Res; 2018 Jun; 24(12):2828-2843. PubMed ID: 29599409
    [No Abstract]   [Full Text] [Related]  

  • 12. Drug Response Prediction by Globally Capturing Drug and Cell Line Information in a Heterogeneous Network.
    Le DH; Pham VH
    J Mol Biol; 2018 Sep; 430(18 Pt A):2993-3004. PubMed ID: 29966608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PERCEPTION predicts patient response and resistance to treatment using single-cell transcriptomics of their tumors.
    Sinha S; Vegesna R; Mukherjee S; Kammula AV; Dhruba SR; Wu W; Kerr DL; Nair NU; Jones MG; Yosef N; Stroganov OV; Grishagin I; Aldape KD; Blakely CM; Jiang P; Thomas CJ; Benes CH; Bivona TG; Schäffer AA; Ruppin E
    Nat Cancer; 2024 Jun; 5(6):938-952. PubMed ID: 38637658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In silico drug combination discovery for personalized cancer therapy.
    Jeon M; Kim S; Park S; Lee H; Kang J
    BMC Syst Biol; 2018 Mar; 12(Suppl 2):16. PubMed ID: 29560824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical drug response prediction from preclinical cancer cell lines by logistic matrix factorization approach.
    Emdadi A; Eslahchi C
    J Bioinform Comput Biol; 2022 Apr; 20(2):2150035. PubMed ID: 34923927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DeepDRK: a deep learning framework for drug repurposing through kernel-based multi-omics integration.
    Wang Y; Yang Y; Chen S; Wang J
    Brief Bioinform; 2021 Sep; 22(5):. PubMed ID: 33822890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Precision medicine: A major step forward in specific situations, a myth in refractory cancers?].
    Albin N; Mc Leer A; Sakhri L
    Bull Cancer; 2018 Apr; 105(4):375-396. PubMed ID: 29501208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid identification and validation of novel targeted approaches for Glioblastoma: A combined ex vivo-in vivo pharmaco-omic model.
    Daher A; de Groot J
    Exp Neurol; 2018 Jan; 299(Pt B):281-288. PubMed ID: 28923369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outlier analysis of functional genomic profiles enriches for oncology targets and enables precision medicine.
    Zhu Z; Ihle NT; Rejto PA; Zarrinkar PP
    BMC Genomics; 2016 Jun; 17():455. PubMed ID: 27296290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genomic signatures defining responsiveness to allopurinol and combination therapy for lung cancer identified by systems therapeutics analyses.
    Tavassoly I; Hu Y; Zhao S; Mariottini C; Boran A; Chen Y; Li L; Tolentino RE; Jayaraman G; Goldfarb J; Gallo J; Iyengar R
    Mol Oncol; 2019 Aug; 13(8):1725-1743. PubMed ID: 31116490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.